Europe News
Filter News
Found 77,008 articles
-
Sweden-based Sobi and Swiss-based Novimmune announced the U.S. approval of Gamifant (emapalumab-lzsg) to treat an ultra-rare disease in adults and children. Sobi’s U.S. offices are in Waltham, Mass.
-
Since taking over as chief executive officer of Swiss pharma giant Novartis, Vas Narasimhan has been actively reshaping the company to focus on therapies that will drive revenue well into the future.
-
A Small Group of Pharma Companies Is Making the Bulk of Medicines Necessary for Developing Countries
11/21/2018
There are 7 billion people in the world. Of those, 5 billion have access to life-saving medications, while 2 billion do not. That is a gap that pharmaceutical companies can help close through increased R&D programs, logistical initiatives and the lowering of prices, the Access to Medicine Foundat... -
Research Roundup for November 21: Early Cancer Diagnosis, Carbs or No Carbs, and Why You Love/Hat...
11/21/2018
Even with the Thanksgiving week, there is interesting and exciting research being conducted and published. Here’s a look. -
Medivir Nominates MIV-828 as a Candidate Drug for the Treatment of Hematological Malignancies
11/21/2018
Medivir AB today announces that MIV-828 has been nominated as a candidate drug (CD) for the treatment of acute myeloid leukemia (AML) and other hematological malignancies.
-
Hansa Medical AB to Present at the Evercore ISI HealthConX Conference
11/21/2018
Søren Tulstrup, President and CEO of Hansa Medical, will present at the Evercore ISI HealthConX Conference at the Boston Harbor Hotel on Tuesday, November 27, 2018 at 10:35 am ET.
-
Kleresca® Employs Industrial Postdoc Researcher to Investigate Impact of Fluorescent Light Energy (FLE) on Human Immune System
11/21/2018
Kleresca® has strengthened its research activities by employing an industrial postdoc to investigate the impact of FLE on skin macrophages.
-
Getinge Capital Markets Day
11/21/2018
Today at Getinge's Capital Markets Day the President & CEO Mattias Perjos, together with the Getinge Executive Team, will present the strategy and related Business Area plans needed to improve company performance.
-
After announcing a potential snag with the European Commission last month, Takeda said this morning that it received clearance for its acquisition of Shire. The clearance is conditional on addressing overlaps in the companies’ inflammatory bowel disease businesses.
-
The Biotechnology Industry Organization (BIO) published the fifth edition of the Building the Bioeconomy report recently. The report studied 28 different indicators and provided analysis and insight into the biotech environment for 33 countries. The goal of the report is to determine how successf...
-
Under the terms of the deal, Roivant is paying iNtRON Bio $10 million upfront. iNtRON will be eligible for milestone payments. When the first patient receives treatment in a U.S. Phase II clinical trial scheduled for 2019, the first milestone will be $30 million.
-
Merck KGaA, Darmstadt, Germany Enters Field of Big Data With Joint Venture With Palantir Technolo...
11/20/2018
Germany’s pharma giant Merck KGaA, Darmstadt, Germany and Silicon Valley data analytics company Palantir Technologies are forming a joint venture called Syntropy. Syntropy will be based in Boston and will focus on cancer data analytics tools. -
Less than a week after Boston Scientific announced that it was undergoing a restructuring that could result in some job losses, the company announced that it will acquire U.K.-based BTG plc., a surgical device manufacturer for about $4.2 billion.
-
PellePharm’s Phase III Skin Disease Trial Is Back on Track Following Agreement With LEO Pharma
11/20/2018
Denmark-based LEO Pharma and California rare disease drugmaker PellePharm entered into a strategic collaboration worth $760 million to address unmet needs in multiple orphan skin diseases, such as Gorlin Syndrome and High-Frequency Basal Cell Carcinomas (BCCs), two rare forms of skin cancer. -
FDA Approves Gamifant® (emapalumab), the First and Only Treatment for Primary Haemophagocytic Lymphohistiocytosis (HLH)
11/20/2018
Swedish Orphan Biovitrum AB today announce that the US Food and Drug Administration (FDA) has approved Gamifant® (emapalumab-lzsg), an interferon gamma (IFNγ) blocking antibody for the treatment of paediatric (new born and older) and adult patients with primary haemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance to conventional HLH therapy.
-
Mylan Initiates Voluntary Nationwide Recall of 15 Lots of Valsartan Tablets, USP, Amlodipine and Valsartan Tablets, USP, and Valsartan and Hydrochlorothiazide Tablets, USP, Due to the Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine)
11/20/2018
Mylan N.V. today announced that its U.S. based Mylan Pharmaceuticals business is conducting a voluntary nationwide recall to the consumer level of select lots of Valsartan-containing products, including six lots of Amlodipine and Valsartan Tablets, USP (including the 5mg/160mg, 10mg/160mg, and 10mg/320mg strengths), seven lots of Valsartan Tablets, USP (including 40 mg, 80 mg, 160 mg, and 320 mg strengths), and two lots of Valsartan and Hydrochlorothiazide Tablets, USP 320mg/25mg strength.
-
Mylan Statement in Response to FDA Warning Letter Relating to Morgantown Plant
11/20/2018
Mylan N.V. today commented on a Warning Letter issued by the U.S. Food and Drug Administration (FDA) on Nov. 9, 2018, relating to its manufacturing facility in Morgantown, West Virginia.
-
Allergan to Present at the 2018 Citi Global Healthcare Conference
11/20/2018
Allergan plc today announced that Chairman and CEO Brent Saunders will participate in a fireside chat at the 2018 Citi Global Healthcare Conference in New York City.
-
Global Hydronephrosis Therapies Market 2019-2023 | High Prevalence of Kidney Diseases Impacting the Market Growth | Technavio
11/20/2018
The global hydronephrosis therapies market 2019-2023 is expected to post a CAGR of more than 9% during the forecast period, according to the latest market research report by Technavio.
-
Global Guillain-Barré Syndrome Treatment Market 2019-2023 | Recent Approvals of immunoglobulins to Boost Demand | Technavio
11/20/2018
Technavio analysts forecast the global Guillain-Barré syndrome treatment market to grow at a CAGR of over 5% during the forecast period, according to their latest market research report